Venture capital (VC) firms Longitude Capital, Acadia Woods Partners, Artiman Ventures, investment bank JP Morgan, and Bright Capital, the corporate venturing unit of Russia-based industrial conglomerate Ru-Com Group, participated in the CardioDx round as new investors.

Siemens misses public mention in U-Systems' latest round.

Venture capital firm New Leaf Venture Partners led the C round for iRhythm Technologies as a new investor, and was joined by peers Mohr Davidow Ventures and Synergy Life Science Partners as well as St Jude.

Novo joins venture capital firms SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners that had backed its CHF13.5m first close of the A round in November.

The $22m round for ProFibrix was co-led by venture capital firm Vesalius Biocapital and Inkef Capital, a quasi-corporate venturing joint venture between pension funds ABP and Omers in its first deal after being set up in June last year.

Four investors have agreed to back Shanghai Pharmaceuticals with $550m to support its initial public offering. Pfizer and Bank of China will each invest $50m, Singapore state-backed Temasek will buy $300m of shares and Malaysia-based conglomerate Guoco Group the remaining $150m.

As part of a series of interviews with leading venture investors and developers, Andrew Gaule, founder of the H-I Network and Corporate Venturing Network, talks to William Taranto (pictured), managing director of Global Health Innovation Fund, Merck.

As part of the $12m B round investment, Heath Lukatch and Tiba Aynechi, a partner and principal in Novo Ventures respectively, join Cianna's board.

Novartis Venture Fund and Venture Investors, a venture capital (VC) firm investing in university technology transfer start-ups throughout the Midwest of America, co-led the $22m B round for Akebia Therapeutics.